quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Anal Cancer

Conditions

Anal Cancer, Nonneoplastic Condition, Penile Cancer, Precancerous Condition

Trial Timeline

Jun 28, 2011 → Dec 12, 2017

NCT ID

NCT01209325

About quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine

quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine is a phase 2 stage product being developed by Merck for Anal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01209325. Target conditions include Anal Cancer, Nonneoplastic Condition, Penile Cancer.

What happened to similar drugs?

6 of 12 similar drugs in Anal Cancer were approved

Approved (6) Terminated (0) Active (6)

✅aspirin, acetaminophen, ibuprofen, naproxen, celecoxib, rofecoxibJohnson & JohnsonApproved

✅Bupivacaine Liposome InjectionJiangsu Hengrui MedicineApproved

🔄Ibuprofen 600 mg Immediate Release/Extended Release CapletPfizerPhase 3

🔄HSK21542 Injection + Tramadol hydrochloride + placeboHaisco Pharmaceutical GroupPhase 3

🔄HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3

🔄carboplatin + paclitaxel + retifanlimabIncytePhase 3

🔄HTX-011 + Ibuprofen + Acetaminophen + Celecoxib + +/- Bupivacaine HCl + HTX-011Heron TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01209325	Phase 2	Completed	Jun 28, 2011	Dec 12, 2017	Anal Cancer
NCT00733122	Phase 3	Withdrawn	Oct 1, 2009	Oct 1, 2013	HPV Infections
NCT00635830	Phase 1	Completed	Mar 1, 2008	Apr 1, 2008	HPV Infections
NCT00380367	Phase 3	Completed	May 3, 2007	Feb 4, 2008	Papillomavirus Infections

Competing Products

20 competing products in Anal Cancer

See all competitors

Product	Company	Stage	Hype Score
aspirin, acetaminophen, ibuprofen, naproxen, celecoxib, rofecoxib	Johnson & Johnson	Approved	43
Acetaminophen	Johnson & Johnson	Phase 2	42
HRF2105 patch + Loxoprofen patch + placebo	Jiangsu Hengrui Medicine	Phase 2	31
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparation	Jiangsu Hengrui Medicine	Phase 1	29
Bupivacaine Liposome Injection	Jiangsu Hengrui Medicine	Approved	50
Paracetamol injection + Normal Saline injection + Morhpine PCA	Jiangsu Hengrui Medicine	Phase 2/3	38
Bupivacaine Liposome Injection + Bupivacaine Hydrochloride Injection	Jiangsu Hengrui Medicine	Phase 2	42
Vandetanib + Capecitabine + Oxaliplatin + Bevacizumab	AstraZeneca	Phase 1	29
Org 28611 + morphine sulfate + Placebo	Merck	Phase 2	27
Pembrolizumab	Merck	Phase 2	35
Cetuximab + Mitomycin C + 5-Fluoruracil	Merck	Phase 1	29
Pembrolizumab + Paclitaxel + Carboplatin + Pembrolizumab	Merck	Phase 2	42
9-valent HPV vaccination	Merck	Phase 2	42
Gardasil	Merck	Pre-clinical	22
Sample collection	Novartis	Phase 2	42
Atezolizumab plus Tiraglolumab	Roche	Phase 2	42
MPDL3280A + mDCF	Roche	Phase 2	35
panitumumab, mytomicin C, 5-FU, radiation	Amgen	Phase 2	35
oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + marketed oxycodone hydrochloride	Pfizer	Phase 1	29
Ibuprofen 600 mg Immediate Release/Extended Release Caplet	Pfizer	Phase 3	40